These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2566801)

  • 1. Apomorphine test for dopaminergic responsiveness.
    Lancet; 1989 Jun; 1(8649):1262-3. PubMed ID: 2566801
    [No Abstract]   [Full Text] [Related]  

  • 2. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P; Del Dotto P; Napolitano A; Pardini C; Bonuccelli U
    Riv Neurol; 1990; 60(6):221-3. PubMed ID: 2100046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
    Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
    Miranda M; Saéz D
    Rev Med Chil; 1995 Mar; 123(3):326-9. PubMed ID: 8525172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The apomorphine test in parkinsonian syndromes.
    D'Costa DF; Abbott RJ; Pye IF; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):870-2. PubMed ID: 1744640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Apomorphine test in Parkinson disease--dose and corresponding parameters].
    Pinter MM; Helscher RJ; Sattler AP
    Wien Klin Wochenschr; 1993; 105(16):472-5. PubMed ID: 8212705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease.
    Müller T; Benz S; Börnke C; Russ H; Przuntek H
    J Neural Transm (Vienna); 2003 Jun; 110(6):603-9. PubMed ID: 12768356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Limited value of the apomorphine test in Parkinson disease].
    Roos RA; van Laar T; van Hilten JJ
    Ned Tijdschr Geneeskd; 1994 Jul; 138(27):1374-6. PubMed ID: 7913520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine test in the assessment of parkinsonian patients: a meta-analysis.
    Hughes AJ
    Adv Neurol; 1999; 80():363-8. PubMed ID: 10410742
    [No Abstract]   [Full Text] [Related]  

  • 12. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC; Burguera JA
    Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
    Hughes AJ; Lees AJ; Stern GM
    Lancet; 1990 Jul; 336(8706):32-4. PubMed ID: 1973218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].
    Roth J; Růzicka E; Mecír P
    Cas Lek Cesk; 1994 Nov; 133(21):665-7. PubMed ID: 7805088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes.
    Barker R; Duncan J; Lees A
    Lancet; 1989 Mar; 1(8639):675. PubMed ID: 2564495
    [No Abstract]   [Full Text] [Related]  

  • 16. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The apomorphine test in Parkinson's disease: diagnostic value].
    Linazasoro G
    Neurologia; 1993 Nov; 8(9):288-90. PubMed ID: 8297620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome.
    Yokochi M
    Adv Neurol; 1993; 60():548-52. PubMed ID: 8420189
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
    Imai H; Nakamura T; Kondo T; Narabayashi H
    Adv Neurol; 1993; 60():622-5. PubMed ID: 8420201
    [No Abstract]   [Full Text] [Related]  

  • 20. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.
    Gasser T; Schwarz J; Arnold G; Trenkwalder C; Oertel WH
    Arch Neurol; 1992 Nov; 49(11):1131-4. PubMed ID: 1444878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.